Literature DB >> 18453855

Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.

J Michael Kilby1, Ha Youn Lee, J Darren Hazelwood, Anju Bansal, R Patterson Bucy, Michael S Saag, George M Shaw, Edward P Acosta, Victoria A Johnson, Alan S Perelson, Paul A Goepfert.   

Abstract

OBJECTIVE: Compare the initial phases of virologic decay when acute/early and advanced HIV-infected adults are administered the same treatment regimen.
DESIGN: Mathematical modeling of a previously completed prospective treatment pilot study involving treatment-naive patients with early and advanced immunosuppression.
METHODS: We analyzed data from a treatment protocol in which 18 individuals with acute or recent HIV-1 seroconversion and six patients with advanced AIDS were administered the same four-drug antiretroviral regimen. Initial treatment responses were compared by fitting a mathematical model to frequent viral load measurements in order to calculate the first and second phase kinetics of viral clearance, and also by comparing viral load suppression over 24 weeks. Patients were also comprehensively compared in terms of protease inhibitor drug levels, HIV-specific immune responses at baseline, and the presence of drug resistance-conferring mutations.
RESULTS: There was no statistically meaningful difference in first phase clearance of comparable high-level viremia in the two groups, whether protease inhibitor levels were inserted into the model or 100% antiviral drug effectiveness was assumed. In contrast, acute/early patients had inferior sustained responses than advanced patients, reflecting erratic adherence.
CONCLUSIONS: Despite many years of intervening immune destruction, the initial virologic decay on therapy appears to be the same at the extremes of the HIV disease spectrum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18453855      PMCID: PMC3899827          DOI: 10.1097/QAD.0b013e3282fbd1da

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  Treatment of acute HIV-1 infection: is it coming of age?

Authors:  Sabine Kinloch-de Loes
Journal:  J Infect Dis       Date:  2006-08-15       Impact factor: 5.226

2.  Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection.

Authors:  H Putter; J M Prins; S Jurriaans; M Roos; N M Ferguson; R van Praag; L van der Hoek; H Schuitemaker; R M Anderson; J Goudsmit; J M Lange; F de Wolf
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

3.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.

Authors:  B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

4.  Determining the relative efficacy of highly active antiretroviral therapy.

Authors:  Michael Louie; Christine Hogan; Michele Di Mascio; Arlene Hurley; Viviana Simon; James Rooney; Nancy Ruiz; Scott Brun; Eugene Sun; Alan S Perelson; David D Ho; Martin Markowitz
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

5.  Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

Authors:  Daniel R Kuritzkes; Heather J Ribaudo; Kathleen E Squires; Susan L Koletar; Jorge Santana; Sharon A Riddler; Richard Reichman; Cecilia Shikuma; William A Meyer; Karin L Klingman; Roy M Gulick
Journal:  J Infect Dis       Date:  2007-03-06       Impact factor: 5.226

6.  Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.

Authors:  Bradley H Edwards; Anju Bansal; Steffanie Sabbaj; Janna Bakari; Mark J Mulligan; Paul A Goepfert
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.

Authors:  G R Kaufmann; P Cunningham; A D Kelleher; J Zaunders; A Carr; J Vizzard; M Law; D A Cooper
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

9.  Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.

Authors:  Michele L Turner; Kedria Reed-Walker; Jennifer R King; Edward P Acosta
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-02-05       Impact factor: 3.205

10.  Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

Authors:  M Altfeld; E S Rosenberg; R Shankarappa; J S Mukherjee; F M Hecht; R L Eldridge; M M Addo; S H Poon; M N Phillips; G K Robbins; P E Sax; S Boswell; J O Kahn; C Brander; P J Goulder; J A Levy; J I Mullins; B D Walker
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

View more
  15 in total

1.  CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection.

Authors:  Sonya L Heath; Steffanie Sabbaj; Anju Bansal; J Michael Kilby; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

2.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  SPMM: estimating infection duration of multivariant HIV-1 infections.

Authors:  Tanzy M T Love; Sung Yong Park; Elena E Giorgi; Wendy J Mack; Alan S Perelson; Ha Youn Lee
Journal:  Bioinformatics       Date:  2015-12-31       Impact factor: 6.937

4.  Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.

Authors:  Cynthia L Gay; Ashley J Mayo; Chelu K Mfalila; Haitao Chu; Anna C Barry; JoAnn D Kuruc; Kara S McGee; Melissa Kerkau; Joe Sebastian; Susan A Fiscus; David M Margolis; Charles B Hicks; Guido Ferrari; Joseph J Eron
Journal:  AIDS       Date:  2011-04-24       Impact factor: 4.177

5.  Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy.

Authors:  Jessie K Edwards; Stephen R Cole; Adaora Adimora; Jason Fine; Jeff Martin; Joseph Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2015-02-01       Impact factor: 3.731

6.  Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.

Authors:  Tadashi Kikuchi; Yukie Iwabu; Takuya Tada; Ai Kawana-Tachikawa; Michiko Koga; Noriaki Hosoya; Shigeru Nomura; Zabrina L Brumme; Heiko Jessen; Florencia Pereyra; Alicja Trocha; Bruce D Walker; Aikichi Iwamoto; Kenzo Tokunaga; Toshiyuki Miura
Journal:  J Virol       Date:  2015-02-25       Impact factor: 5.103

7.  Conceptualizing a Human Right to Prevention in Global HIV/AIDS Policy.

Authors:  Benjamin Mason Meier; Kristen Nichole Brugh; Yasmin Halima
Journal:  Public Health Ethics       Date:  2012-12-05       Impact factor: 1.940

8.  In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.

Authors:  Joseph K Wong; Matthew C Strain; Rodin Porrata; Elizabeth Reay; Sumathi Sankaran-Walters; Caroline C Ignacio; Theresa Russell; Satish K Pillai; David J Looney; Satya Dandekar
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

9.  Quantifying the Dynamics of HIV Decline in Perinatally Infected Neonates on Antiretroviral Therapy.

Authors:  Sinead E Morris; Luise Dziobek-Garrett; Renate Strehlau; Juliane Schröter; Stephanie Shiau; Anet J N Anelone; Maria Paximadis; Rob J de Boer; Elaine J Abrams; Caroline T Tiemessen; Louise Kuhn; Andrew J Yates
Journal:  J Acquir Immune Defic Syndr       Date:  2020-10-01       Impact factor: 3.731

10.  HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection.

Authors:  Victor Y Du; Anju Bansal; Jonathan Carlson; Jesus F Salazar-Gonzalez; Maria G Salazar; Kristin Ladell; Stephanie Gras; Tracy M Josephs; Sonya L Heath; David A Price; Jamie Rossjohn; Eric Hunter; Paul A Goepfert
Journal:  J Immunol       Date:  2016-03-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.